Dive deep into the CRISPR investment boom that's reshaping biotech portfolios worldwide.
This episode breaks down why venture capital surged 33% to $28.1 billion, which CRISPR companies are attracting smart money, and how third-generation gene editing tools are creating billion-dollar market opportunities.
We explore Scribe Therapeutics' $100M Series B, Xaira's record $1B raise, and why established pharmaceutical partnerships are validating commercial potential.
Perfect for investors, entrepreneurs, and anyone tracking biotech's most lucrative transformation since the Human Genome Project.
#CRISPR #BiotechInvesting #VentureCapital #GeneEditing #BiotechStocks #LifeSciences #TechInvesting #StartupFunding #BioRevolution #InvestmentStrategy
